For example, the Center for Psychedelic & Consciousness Research at Johns Hopkins University is looking at psilocybin, MDMA (aka ecstasy), and other psychedelics for treating many conditions.
The possible targets for psychedelic medicine include PTSD (see This Week in Data, below), depression, anxiety, and addiction.
These are among the most widespread mental health conditions, so from a market size perspective, there is something here. Not to mention, these compounds have been used by humans for generations, so in a way we’ve been running “human challenge trials” of sorts with these for millennia.
Even the oft-demonized LSD has been known to be relatively well tolerated even in large doses (ahem, not medical advice).
As we argued in our Healthcare Insights newsletter today, “it may only be a matter of time before the FDA grants approval for psychoactive compounds to be used therapeutically.” There are healthcare startups working in this area, and we were onto this trend way back in 2019.
If decriminalization really takes off, your morning micro-dose will be no more remarkable as a wellness routine than that dropper of CBD on your bedside table.
BTW, clients are able to read our just-published 80-slide State Of Wellness report for all the details on how retail and CPG are responding to this trend they can’t ignore.